BioXcel Therapeutics Inc. (NASDAQ: BTAI) started the day on November 23, 2022, with a price increase of 5.37% at $15.51. During the day, the stock rose to $15.80 and sunk to $14.61 before settling in for the price of $14.72 at the close. Taking a more long-term approach, BTAI posted a 52-week range of $8.80-$24.72.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -7.00%. This publicly-traded company’s shares outstanding now amounts to $28.02 million, simultaneously with a float of $18.99 million. The organization now has a market capitalization sitting at $444.98 million. At the time of writing, stock’s 50-day Moving Average stood at $12.39, while the 200-day Moving Average is $14.36.
BioXcel Therapeutics Inc. (BTAI) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. BioXcel Therapeutics Inc.’s current insider ownership accounts for 32.23%, in contrast to 47.90% institutional ownership. According to the most recent insider trade that took place on Nov 11, this organization’s Director sold 32,550 shares at the rate of 15.00, making the entire transaction reach 488,250 in total value, affecting insider ownership by 0. Preceding that transaction, on Nov 10, Company’s Director sold 27,450 for 15.00, making the whole transaction’s value amount to 411,750. This particular insider is now the holder of 0 in total.
BioXcel Therapeutics Inc. (BTAI) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2022, the organization reported -$1.35 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$1.22) by -$0.13. This company achieved a return on equity of -49.93. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.32 per share during the current fiscal year.
BioXcel Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -7.00% and is forecasted to reach -5.35 in the upcoming year.
BioXcel Therapeutics Inc. (NASDAQ: BTAI) Trading Performance Indicators
Let’s observe the current performance indicators for BioXcel Therapeutics Inc. (BTAI). It’s Quick Ratio in the last reported quarter now stands at 10.30. The Stock has managed to achieve an average true range (ATR) of 1.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4449.82.
In the same vein, BTAI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.90, a figure that is expected to reach -1.45 in the next quarter, and analysts are predicting that it will be -5.35 at the market close of one year from today.
Technical Analysis of BioXcel Therapeutics Inc. (BTAI)
If we take a close look at the recent performances of BioXcel Therapeutics Inc. (NASDAQ: BTAI), its last 5-days Average volume was 0.21 million that shows plunge from its year to date volume of 0.47 million. During the previous 9 days, stock’s Stochastic %D was recorded 50.64% While, its Average True Range was 1.19.